# HFE Genetic Testing Workflow: Who to Test and How to Interpret > HFE genotyping follows elevated iron studies or first-degree relatives of known HH—not unselected population screening. Homozygotes, compound hets, and simple hets map to different next steps. *Published 2026-07-10 · Updated 2026-07-10 · By Elena Voss* In short Order **HFE genotyping** after elevated iron studies or for **first-degree relatives**—not as unselected population screening. Interpret **C282Y/C282Y**, compound hets, and simple hets differently, then map each result to ferritin stage and unloading need. Genetics without an iron panel is a riddle. An iron panel without genetics in a high-risk family is a missed prevention chance. The workflow is dual on purpose. *This article is informational and editorial only. It is not medical advice, diagnosis, or a treatment plan. Numbers and literature ranges cited here are not personal prescriptions. Consult a qualified clinician before changing medications, supplements, diet, equipment, or management of a diagnosed condition. Seek urgent care for emergencies.* ## What are the indication rules for HFE testing? After abnormal transferrin saturation and/or ferritin, perform HFE mutation analysis per AASLD Recommendation 3. Screen first-degree relatives with iron studies and HFE analysis per Recommendation 5. Societies recommend against general population genetic screening because penetrance is incomplete and variable across ancestries. Consider hemochromatosis evaluation in porphyria cutanea tarda, chondrocalcinosis, hepatocellular carcinoma, type 1 diabetes contexts, abnormal iron studies, and unexplained chronic liver disease—while remembering secondary iron. The [CDC](https://www.cdc.gov/hereditary-hemochromatosis/about/index.html) stresses family history conversations, especially siblings, and reminds readers that most genotypically affected people never develop complications. ## How should common genotypes be interpreted? Map results into a hierarchy: C282Y/C282Y, compound heterozygote, H63D/H63D (less classic), simple heterozygotes, and wild-type. Adults who are C282Y/C282Y or compound heterozygotes with high ferritin can enter phlebotomy pathways; normal ferritin supports yearly iron studies rather than reflexive induction. C282Y heterozygotes and H63D heterozygotes are generally not at risk for progressive symptomatic overload. Overcalling simple heterozygosity as having hemochromatosis creates lifelong anxiety and unnecessary treatment. Under-calling compound heterozygotes with high ferritin delays care that could prevent fibrosis. Genotype-to-action sketch ResultTypical next step C282Y/C282Y + high ferritinUnload / stage liver if high risk C282Y/C282Y + normal ferritinPeriodic iron studies Compound het + high ferritinPhenotype-driven unloading Simple hetUsually reassure; minor marker noise possible Wild-type + overload phenotypeSecondary workup ± non-HFE panel ## How do partner testing and cascade logistics work? For offspring risk counseling, testing the other parent of a child of a proband can show obligate heterozygosity and spare unnecessary child testing when appropriate. Adult first-degree relatives remain the cascade core. Direct-to-consumer genetics without iron panel follow-up is an anti-pattern; so is universal newborn HFE screening as default editorial advice without society support. With genetic testing available, liver biopsy is not routinely required for diagnosis of HFE hereditary hemochromatosis; it remains mainly for fibrosis staging when ferritin and enzymes signal risk. The [AASLD guideline](https://pmc.ncbi.nlm.nih.gov/articles/PMC3149125/) remains the primary codified source for these decision rules in U.S. practice discussions. ## What interpretation errors cause the most harm? DTC genetics without labs. Telling simple heterozygotes they have disease. Reassuring on genotype alone when ferritin is already over 1000 with high enzymes. Ignoring compound heterozygotes who do have high ferritin. Stopping at HFE-negative when severe phenotype demands non-HFE panels and imaging. Codified rule: genotype after or with phenotype markers; interpret genotype class then map to ferritin stage; cascade first-degree relatives systematically; escalate beyond HFE when severe phenotype is HFE-negative; never use genotype alone as a cirrhosis safety certificate when labs already scream staging need for the liver. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. Editorial note: ranges and protocol bands cited here are literature and guideline context for shared decision-making with clinicians—not self-directed treatment schedules, home lab targets, or substitute care for emergencies or progressive organ disease. ## Sources 1. [AASLD testing recommendations](https://pmc.ncbi.nlm.nih.gov/articles/PMC3149125/) 2. [No population screening consensus](https://www.aasld.org/liver-fellow-network/core-series/clinical-pearls/deciphering-code-iron-overload) 3. [CDC family genetic testing](https://www.cdc.gov/hereditary-hemochromatosis/about/index.html) --- Source: https://healthcanon.com/metabolic-health/hfe-genetic-testing-workflow Index: https://healthcanon.com/llms.txt · Full text: https://healthcanon.com/llms-full.txt